Sunday June 9, 16:30–18:30. Room W-3001, Moscone Center, San Francisco, California
- Introduction and research question. Gilles R. Dagenais, MD
- Background. Rafael Diaz, MD
- Design and baseline characteristics and secondary outcomes testing. Matthew C. Riddle, MD
- Study conduct (adherence, retention, A1c effect, weight, etc.) Helen Colhoun, MD
- Cardiovascular outcomes. Hertzel C. Gerstein, MD, MSc, FRCPC
- Safety. Jeffrey L. Probstfield, MD
- Summary and implications. Lars Rydén, MD, PhD
- Independent commentary. Sophia Zoungas, MBBS (Hons), PhD, FRACP
Top-line results for the REWIND trial have stated that superiority was achieved. We are keenly awaiting the full report to fully understand the benefit of a GLP-1RAs in a population of people without established cardiovascular disease. Unlike prior trials with GLP-1RAs the majority of this participants do not have atherosclerotic cardiovascular disease.